## Contents

**Highlights of This Issue 2009**

FROM THE EDITOR-IN-CHIEF

- **2011**  
  The Patient Impact Factor

THE BEST OF MCT–10 YEARS

- **2012**  
  Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer  
  David J. Bearss

- **2013**  
  First Report of Functional Chk1 siRNA Studies Applied to Drug Discovery  
  Zehan Chen

- **2015**  
  The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies  
  Dana Hu-Lowe, Nicoletta Brega, and Shem Patyna

- **2016**  
  PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235  
  Sauveur-Michel Maira

- **2017**  
  Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions  
  Florence I. Raynaud and Paul Workman

- **2019**  
  The Discovery of Lapatinib (GW572016)  
  David Rusnak and Tona M. Gilmer

- **2020**  
  Methylation Profiling of Lung Cancer: A Decade of Progress  
  Shinichi Toyooka and Adi F. Gazdar

- **2021**  
  MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between -omic and Hypothesis-Driven Research  
  John N. Weinstein

- **2022**  
  Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer  
  Xuexyan Wang, Gerald McMahon, and Kenneth E. Lipson

**REVIEW**

- **2024**  
  Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models  
  James G. Christensen

- **2025**  
  Lapatinib: Functional Genomics Study Leads to Insights into Mechanism of Action  
  Tona M. Gilmer

- **2026**  
  Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST  
  Andrew K. Godwin

- **2028**  
  The Importance of PK/PD Data-Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics  
  Rakesh Kumar and Benjamin Suttle

- **2029**  
  Bortezomib: Understanding the Mechanism of Action  
  Bilal Piperdi, Yi-He Ling, Leonard Liebes, Franco Muggia, and Roman Perez-Soler

- **2031**  
  Starting with the ABCs: Akt in Breast Cancer  
  Kip A. West and Phillip A. Dennis

- **2032**  
  Cell Line Models Identify Different Sensitivity of Mutant Forms of c-KIT to Kinase Inhibitory Drugs and Predict the Response of Patients to Therapy  
  Leonie K. Ashman

- **2034**  
  Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma  
  Teru Hideshima, Paul G. Richardson, and Kenneth C. Anderson

Downloaded from mct.aacrjournals.org on April 19, 2017. © 2011 American Association for Cancer Research.
THERAPEUTIC DISCOVERY

Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Kruppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Agneszka B. Bialkowska, Melissa Crisp, Thomas Bannister, Yuanjun He, Sarwat Chowdhury, Stephan Schürer, Peter Chase, Timothy Spencer, Franck Madoux, Chenli Tian, Peter Hodder, Daniel Zaharevitz, and Vincent W. Yang

Discovery and Evaluation of Inhibitors of Human Ceramidase
Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, and Charles D. Smith

Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells
Carolyn M. Klinge, Brandie N. Radde, Yoannis Imbert-Fernandez, Yun Teng, Margarita M. Ivanova, Sabra M. Abner, and Alexandra L. Martin

A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, and Malcolm Finlayson

Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks
Ioannis Prassas, George S. Karagiannis, Ihor Batruch, Apostolos Dimitromanolakis, Alessandro Datti, and Eleftherios P. Diamandis

PRECLINICAL DEVELOPMENT

Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways
Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, and Razelle Kurzrock

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, and Eileen A. Friedman

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis
Dharmalingam Subramaniam, Nathan D. Nichols, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen, and Shrikant Anant

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger, Christian Moser, Claus Hellerbrand, Maria E. Mycielska, Gabriel Glockzin, Hans J. Schlitt, Edward K. Geissler, Olivier Stoldtzing, and Sven A. Lang
MOLECULAR MEDICINE IN PRACTICE

Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Julie Stewart, Wayne Blosser, James Cook, Debra Young, Xiang Ye, Glenn Evans, Kelly Credille, Darryl Ballard, Lysiane Huber, Andrew Capen, Marcio Chedid, Robert Ilaria, Jr., Michele C. Smith, and Louis Stancato

Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation
Anja Uhmann, Hannah Niemann, Bérénice Lammering, Cornelia Henkel, Ina Heß, Frauke Nitzki, Anne Fritsch, Nicole Prüfer, Albert Rosenberger, Christian Dullin, Anke Schraepler, Julia Reifenberger, Stefan Schweyer, Torsten Frietsch, Frank Strutz, Walter Schulz-Schaeffer, and Heidi Hahn

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaoqen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng, and Denis J. McCann

Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

ABOUT THE COVER

Met kinase homology model with its inhibitor, SU11271, docked in the ATP binding site. The cover image was selected from an article previously published in Molecular Cancer Therapeutics, which was chosen in celebration of the 10th anniversary of the journal. For details, see the commentary by Wang and colleagues on page 2022.